Report From J-PULSE Multicenter Registry of Patients With Shock-Resistant Out-of-Hospital Cardiac Arrest Treated With Nifekalant Hydrochloride

• Yasuda Satoshi

  National Cerebral and Cardiovascular Center Tohoku University Graduate School of Medicine

• Sawano Hirotaka

  Saiseikai Senri Hospital, Senri Critical Care Medical Center

• Hazui Hiroshi

  Osaka Mishima Emergency and Critical Care Center

• Ukai Isao

  Osaka University Hospital Trauma and Acute Critical Care Center

• Yokoyama Hiroyuki

  National Cerebral and Cardiovascular Center

• Ohashi Junko

  National Cerebral and Cardiovascular Center Tohoku University Graduate School of Medicine

• Sase Kazuhiro

  Juntendo University Medical School

• Kada Akiko

  National Cerebral and Cardiovascular Center

• Nonogi Hiroshi

  National Cerebral and Cardiovascular Center

• The J-PULSE Investigators

抄録

Background: Nifekalant hydrochloride (NIF) is an intravenous class-III antiarrhythmic agent that purely blocks the K⁺-channel without inhibiting β-adrenergic receptors. The present study was designed to investigate the feasibility of NIF as a life-saving therapy for out-of-hospital ventricular fibrillation (VF). Methods and Results: The Japanese Population-based Utstein-style study with basic and advanced Life Support Education study was a multi-center registry study with 4 participating institutes located at the northern urban area of Osaka, Japan. Eligible patients were those treated with NIF because of out-of-hospital VF refractory to 3 or more precordial shocks and intravenous epinephrine. Between February 2006 and February 2007, 17 patients were enrolled for the study. The time from a call for emergency medical service to the first shock was 12(6-26)min. The time from the first shock to the NIF administration was 25.5(9-264)min and the usage dose of NIF was 25(15-210)mg. When excluding 3 patients in whom percutaneous extracorporeal membrane oxygenation was applied before NIF administration, the rate of return of spontaneous circulation was 86% and the rate of admission alive to the hospital was 79%. One patient developed torsade de pointes. Conclusions: Intravenous administration of NIF seems to be feasible as a potential therapy for advanced cardiac life-support in patients with out-of-hospital VF, and therefore further study is warranted. (Circ J 2010; 74: 2308-2313)<br>

収録刊行物

• Circulation Journal

  Circulation Journal 74 (11), 2308-2313, 2010

  一般社団法人 日本循環器学会

キーワード

• Advanced life support
• Anti-arrhythmic drugs/therapy
• Cardiac arrest
• Defibrillation
• Ventricular fibrillation

詳細情報

• CRID: 1390282680078641408
• NII論文ID: 10026972612
• NII書誌ID: AA11591968
• DOI: 10.1253/circj.cj-09-0759
• COI: 1:STN:280:DC%2BC3cbktFejsQ%3D%3D
• ISSN: 13474820
• ISSN: 13469843
• PubMed: 20877128
• Web Site: http://www.jstage.jst.go.jp/article/circj/74/11/74_CJ-09-0759/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2011109381
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可